Regulatory delays in pharmaceutical pricing decisions are creating critical supply chain vulnerabilities across the healthcare sector. With the Federal cabinet postponing action on 105 essential medicines designated for hardship categories, the healthcare system faces mounting pressures including potential medication shortages and increased counterfeit drug infiltration. The DRAP's price revision recommendations remain pending, leaving pharmacies and patients in uncertainty while counterfeiters exploit the regulatory gap.

Summary auto-generated by AI from the original publisher's content. Editorial standards.